NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").

image for news CRBU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

image for news REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").

image for news MU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Micron Technology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

image for news RVNC Stockholders Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period").

image for news APLT Stockholders Have Opportunity to Lead Applied Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz ("Kaspi.kz" or "the Company") (NASDAQ:KSPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kaspi.kz securities between January 19, 2024 and September 19, 2024, both dates inclusive (the "Class Period").

image for news KSPI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Joint Stock Company Kaspi.kz Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) and certain of its officers.

image for news RIG SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Transocean Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").

image for news NXT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nextracker Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. ("MGP Ingredients" or "the Company") (NASDAQ:MGPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MGP Ingredients securities between May 3, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

image for news MGPI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MGP Ingredients, Inc. to Contact the Firm Today!

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited ("Capri" or "the Company") (NYSE:CPRI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Capri securities between August 10, 2023 and October 24, 2024, both dates inclusive (the "Class Period").

image for news CPRI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Capri Holdings Limited to Contact the Firm Today!

Big Tech stocks like Apple, Tesla and Nvidia are off to a rocky start in 2025. But Wall Street's momentum machine has kept on churning even without their help.

image for news Momentum stocks like Palantir are off to a strong start in 2025 — even after DeepSeek disrupted the ‘Magnificent Seven'

Market timing is ineffective. A diversified, long-term investment strategy with asset allocation is crucial for consistent returns and peace of mind. Low-volatility, high-yield dividend aristocrats like Enbridge, British American Tobacco, and Realty Income offer stable 6.3% income and market-beating returns with a 39% downside in falling markets. Combining these three aristocrats results in a portfolio with low correlation, high returns, and 50% lower volatility than the S&P 500.

image for news Triple Crown Triumph: Three 6% Yielding Dividend Aristocrats For Turbulent Trade Times

PHOENIX--(BUSINESS WIRE)--Carvana (NYSE: CVNA), an industry pioneer for buying and selling used cars online, today released an EV Trends Report highlighting the perspectives of the buyers driving the significant growth in used EV adoption. Highlights from the report1 include: Carvana's EV sales mix continues to lead the used vehicle market as a whole, with 5.7% of Carvana's 2024 sales coming from the category versus 1.3% for the used car industry overall.2 The prospect of saving time and money.

image for news Carvana Customer Survey Reveals Preferences of Car Buyers Driving Rapid Growth of Used EV Category

Urban Edge Properties Reports Fourth Quarter and Full Year 2024 Results — Neutral

UE   Business Wire — February 12, 2025

NEW YORK--(BUSINESS WIRE)--Urban Edge Properties Reports Fourth Quarter and Full Year 2024 Results.

image for news Urban Edge Properties Reports Fourth Quarter and Full Year 2024 Results

Although the trade war has escalated, the stock market remains stable. However, futures markets are pricing in tariffs, especially on energy and foodstuffs. Enbridge and Brookfield Asset Management are exceptional long-term high-yield investments, despite potential short-term volatility due to trade war impacts. Enbridge's cash flow risk from tariffs is minimal, with a strong history of resilience and secure long-term contracts ensuring dividend stability.

image for news Trade War Turbulence: 2 Blue-Chip Bargains To Beat The Potential Coming Market Tumble

BioCryst Launches ORLADEYO® (berotralstat) in Portugal — Neutral

BCRX   GlobeNewsWire — February 12, 2025

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.

image for news BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Dollar General: Buy The Real Estate, The Business, Or Both — Positive

DG   Seeking Alpha — February 12, 2025

Dollar General's expansion is slowing, but the company remains a strong investment due to its rural focus and counter-cyclical resilience. Despite a significant earnings decline, Dollar General's strategic remodels and new product offerings position it for future growth. With a P/E multiple of 12.9x and a 3.2% dividend yield, DG shares offer potential for over 25% annual returns.

image for news Dollar General: Buy The Real Estate, The Business, Or Both

WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The meeting will take place February 28 - March 3, 2025, in San Diego, CA.

image for news Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

The Chefs' Warehouse Reports Fourth Quarter 2024 Financial Results — Neutral

CHEF   GlobeNewsWire — February 12, 2025

RIDGEFIELD, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Chefs' Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs'”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its fourth quarter ended December 27, 2024.

image for news The Chefs' Warehouse Reports Fourth Quarter 2024 Financial Results

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck — Neutral

NEUP   GlobeNewsWire — February 12, 2025

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator

image for news Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck